Alpenglow Biosciences, a pioneer in AI-powered 3D pathology, has announced a strategic multi-year partnership with Virdx, a biophysics AI company specializing in MRI-based cancer detection. The collaboration aims to accelerate the development of next-generation diagnostic tools, combining the strengths of…
MathWorks has announced the launch of MATLAB Copilot, a generative AI–powered assistant designed to boost productivity and accelerate development for engineers, scientists, and researchers. Integrated directly into the MATLAB and Simulink Release 2025b (R2025b), MATLAB Copilot brings the power of…
bioAffinity Technologies Reports Record Q3 2025 Growth for CyPath® Lung Test bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, announced record sales growth for its flagship diagnostic test, CyPath®…
Trilliant Health, a leading analytics and market research firm specializing in healthcare economics, has released its 2025 Trends Shaping the Health Economy Report, offering a comprehensive analysis of six major forces that are expected to define the direction and challenges…
IonQ, Inc., a global leader in quantum computing, has announced the successful completion of its acquisition of Vector Atomic, a California-based pioneer in quantum sensing technology. The all-stock transaction marks a major milestone in IonQ’s evolution toward becoming a fully…
Veristat, a global clinical research organization (CRO) and consultancy specializing in complex clinical studies, announced its participation in the upcoming Clinical Outsourcing Group (COG) – Bay Area 2025 conference, to be held October 21–22, 2025, at the Hyatt Regency San…
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases, announced the successful closing of a $21 million Series A financing. The funding round was led by Avalon BioVentures, with additional participation…
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical-stage cell therapy company, have announced encouraging 36-month follow-up data from exPDite, a Phase I clinical trial investigating bemdaneprocel, an investigational stem cell-derived therapy designed to treat…
The global oncology landscape continues to evolve at a rapid pace, driven by a growing understanding of tumor immunology and the mechanisms that cancer cells exploit to evade immune destruction. Among the most promising targets in this field is CD47,…
Rahway, N.J. – Merck, known as MSD outside the United States and Canada, announced the initiation of three new Phase 2b clinical trials to evaluate the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody designed to target…